By Olga Cotaga

LONDON--GlaxoSmithKline PLC (GSK.LN) said Thursday it has begun phase one of the clinical trial for a antibody that fights tumors.

The antibody is a co-stimulatory receptor that enhances T-cell responses and results in an increased anti-tumor response from the immune system, the pharmaceutical company said.

The study is a two-part clinical trial to evaluate the safety and properties of the antibody in patients with advanced or recurrent solid tumors, the company said. The study aims to identify a dose suitable for development, the company added.

At 1120 GMT, shares were down 7 pence, or 0.5%, at 1552.5 pence valuing the company at 75.61 billion pounds ($110.5 billion).

Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga

(END) Dow Jones Newswires

June 30, 2016 07:58 ET (11:58 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.